Innate Pharma vs TScan Therapeutics
IPHA and TCRX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How IPHA and TCRX compare
TScan Therapeutics grew revenue faster over the last twelve months (−38.4% versus −55.2% for Innate Pharma).
TScan Therapeutics scores higher on the StockData Score (4 against 0 for Innate Pharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | IPHA | TCRX |
|---|---|---|
| Size and price | ||
| Market cap | – | $12.6M |
| Share price | $1.59 | $0.186 |
| Change, 1 year | −30.9% | −83.0% |
| Change, 5 years | −68.3% | −97.9% |
| Beta (5Y) | 0.95 | 0.94 |
| Employees | 181 | 142 |
| StockData Score | ||
| Total score | 0 | 4 (better) |
| Valuation score | 0 | 3 (better) |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 0 | 1 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 2.4× |
| P/B | – | 0.3× |
| FCF yield | – | −888% |
| Fair value | – | $0.857 |
| Margin of safety | – | 78.3% |
| Growth | ||
| Revenue growth (TTM) | −55.2% | −38.4% (better) |
| Revenue growth, 5Y average | −33.6% | 56.9% (better) |
| Profitability | ||
| Operating margin | −600% (better) | −2247% |
| Net margin | – | −2219% |
| FCF margin | −587% (better) | −2153% |
| Return on equity | – | −126% |
| Financial health | ||
| Debt / equity | – | 0.87 |
| Interest coverage | −17.3× (better) | −40.7× |
| Current ratio | 0.60 | 2.03 (better) |
| Altman Z-score | – | −8.19 |
| Piotroski F-score | – | 2 |
| Dividends and buybacks | ||
| Shareholder yield | – | 0.00% |
| Ownership | ||
| Held by institutions | 0.21% | 53.5% |
| Held by insiders | 16.2% | 32.8% |
| Insider net buying, 12 months | – | $146K |
| Short interest, % of float | – | 4.4% |
Go deeper
- IPHA stock overview
- IPHA income statement
- IPHA valuation and score
- TCRX stock overview
- TCRX income statement
- TCRX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.